Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets
Identifieur interne : 001256 ( Pmc/Corpus ); précédent : 001255; suivant : 001257Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets
Auteurs : Jan Ter Meulen ; Alexander Bh Bakker ; Edward N. Van Den Brink ; Gerrit J. Weverling ; Byron Ee Martina ; Bart L. Haagmans ; Thijs Kuiken ; John De Kruif ; Wolfgang Preiser ; Willy Spaan ; Hans R. Gelderblom ; Jaap Goudsmit ; Albert Dme OsterhausSource :
- Lancet (London, England) [ 0140-6736 ] ; 2004.
Abstract
SARS coronavirus continues to cause sporadic cases of severe acute respiratory syndrome (SARS) in China. No active or passive immunoprophylaxis for disease induced by SARS coronavirus is available. We investigated prophylaxis of SARS coronavirus infection with a neutralising human monoclonal antibody in ferrets, which can be readily infected with the virus. Prophylactic administration of the monoclonal antibody at 10 mg/kg reduced replication of SARS coronavirus in the lungs of infected ferrets by 3·3 logs (95% Cl 2·6–4·0 logs; p<0·001), completely prevented the development of SARS coronavirus-induced macroscopic lung pathology (p=0·013), and abolished shedding of virus in pharyngeal secretions. The data generated in this animal model show that administration of a human monoclonal antibody might offer a feasible and effective prophylaxis for the control of human SARS coronavirus infection.
Url:
DOI: 10.1016/S0140-6736(04)16506-9
PubMed: 15220038
PubMed Central: 7112500
Links to Exploration step
PMC:7112500Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets</title><author><name sortKey="Ter Meulen, Jan" sort="Ter Meulen, Jan" uniqKey="Ter Meulen J" first="Jan" last="Ter Meulen">Jan Ter Meulen</name><affiliation><nlm:aff id="aff1">Crucell Holland BV, Leiden, Netherlands</nlm:aff></affiliation></author><author><name sortKey="Bakker, Alexander Bh" sort="Bakker, Alexander Bh" uniqKey="Bakker A" first="Alexander Bh" last="Bakker">Alexander Bh Bakker</name><affiliation><nlm:aff id="aff1">Crucell Holland BV, Leiden, Netherlands</nlm:aff></affiliation></author><author><name sortKey="Van Den Brink, Edward N" sort="Van Den Brink, Edward N" uniqKey="Van Den Brink E" first="Edward N" last="Van Den Brink">Edward N. Van Den Brink</name><affiliation><nlm:aff id="aff1">Crucell Holland BV, Leiden, Netherlands</nlm:aff></affiliation></author><author><name sortKey="Weverling, Gerrit J" sort="Weverling, Gerrit J" uniqKey="Weverling G" first="Gerrit J" last="Weverling">Gerrit J. Weverling</name><affiliation><nlm:aff id="aff1">Crucell Holland BV, Leiden, Netherlands</nlm:aff></affiliation></author><author><name sortKey="Martina, Byron Ee" sort="Martina, Byron Ee" uniqKey="Martina B" first="Byron Ee" last="Martina">Byron Ee Martina</name><affiliation><nlm:aff id="aff5">Department of Virology, Erasmus Medical Center, Rotterdam, Netherlands</nlm:aff></affiliation></author><author><name sortKey="Haagmans, Bart L" sort="Haagmans, Bart L" uniqKey="Haagmans B" first="Bart L" last="Haagmans">Bart L. Haagmans</name><affiliation><nlm:aff id="aff5">Department of Virology, Erasmus Medical Center, Rotterdam, Netherlands</nlm:aff></affiliation></author><author><name sortKey="Kuiken, Thijs" sort="Kuiken, Thijs" uniqKey="Kuiken T" first="Thijs" last="Kuiken">Thijs Kuiken</name><affiliation><nlm:aff id="aff5">Department of Virology, Erasmus Medical Center, Rotterdam, Netherlands</nlm:aff></affiliation></author><author><name sortKey="De Kruif, John" sort="De Kruif, John" uniqKey="De Kruif J" first="John" last="De Kruif">John De Kruif</name><affiliation><nlm:aff id="aff1">Crucell Holland BV, Leiden, Netherlands</nlm:aff></affiliation></author><author><name sortKey="Preiser, Wolfgang" sort="Preiser, Wolfgang" uniqKey="Preiser W" first="Wolfgang" last="Preiser">Wolfgang Preiser</name><affiliation><nlm:aff id="aff2">Institute of Medical Virology, Johann Wolfgang Goethe University, Frankfurt am Main, Germany</nlm:aff></affiliation></author><author><name sortKey="Spaan, Willy" sort="Spaan, Willy" uniqKey="Spaan W" first="Willy" last="Spaan">Willy Spaan</name><affiliation><nlm:aff id="aff4">Department of Medical Microbiology, Leiden University Medical Centre, Leiden, Netherlands</nlm:aff></affiliation></author><author><name sortKey="Gelderblom, Hans R" sort="Gelderblom, Hans R" uniqKey="Gelderblom H" first="Hans R" last="Gelderblom">Hans R. Gelderblom</name><affiliation><nlm:aff id="aff3">Robert Koch-lnstitut, Berlin, Germany</nlm:aff></affiliation></author><author><name sortKey="Goudsmit, Jaap" sort="Goudsmit, Jaap" uniqKey="Goudsmit J" first="Jaap" last="Goudsmit">Jaap Goudsmit</name><affiliation><nlm:aff id="aff1">Crucell Holland BV, Leiden, Netherlands</nlm:aff></affiliation></author><author><name sortKey="Osterhaus, Albert Dme" sort="Osterhaus, Albert Dme" uniqKey="Osterhaus A" first="Albert Dme" last="Osterhaus">Albert Dme Osterhaus</name><affiliation><nlm:aff id="aff5">Department of Virology, Erasmus Medical Center, Rotterdam, Netherlands</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">15220038</idno><idno type="pmc">7112500</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7112500</idno><idno type="RBID">PMC:7112500</idno><idno type="doi">10.1016/S0140-6736(04)16506-9</idno><date when="2004">2004</date><idno type="wicri:Area/Pmc/Corpus">001256</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001256</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets</title><author><name sortKey="Ter Meulen, Jan" sort="Ter Meulen, Jan" uniqKey="Ter Meulen J" first="Jan" last="Ter Meulen">Jan Ter Meulen</name><affiliation><nlm:aff id="aff1">Crucell Holland BV, Leiden, Netherlands</nlm:aff></affiliation></author><author><name sortKey="Bakker, Alexander Bh" sort="Bakker, Alexander Bh" uniqKey="Bakker A" first="Alexander Bh" last="Bakker">Alexander Bh Bakker</name><affiliation><nlm:aff id="aff1">Crucell Holland BV, Leiden, Netherlands</nlm:aff></affiliation></author><author><name sortKey="Van Den Brink, Edward N" sort="Van Den Brink, Edward N" uniqKey="Van Den Brink E" first="Edward N" last="Van Den Brink">Edward N. Van Den Brink</name><affiliation><nlm:aff id="aff1">Crucell Holland BV, Leiden, Netherlands</nlm:aff></affiliation></author><author><name sortKey="Weverling, Gerrit J" sort="Weverling, Gerrit J" uniqKey="Weverling G" first="Gerrit J" last="Weverling">Gerrit J. Weverling</name><affiliation><nlm:aff id="aff1">Crucell Holland BV, Leiden, Netherlands</nlm:aff></affiliation></author><author><name sortKey="Martina, Byron Ee" sort="Martina, Byron Ee" uniqKey="Martina B" first="Byron Ee" last="Martina">Byron Ee Martina</name><affiliation><nlm:aff id="aff5">Department of Virology, Erasmus Medical Center, Rotterdam, Netherlands</nlm:aff></affiliation></author><author><name sortKey="Haagmans, Bart L" sort="Haagmans, Bart L" uniqKey="Haagmans B" first="Bart L" last="Haagmans">Bart L. Haagmans</name><affiliation><nlm:aff id="aff5">Department of Virology, Erasmus Medical Center, Rotterdam, Netherlands</nlm:aff></affiliation></author><author><name sortKey="Kuiken, Thijs" sort="Kuiken, Thijs" uniqKey="Kuiken T" first="Thijs" last="Kuiken">Thijs Kuiken</name><affiliation><nlm:aff id="aff5">Department of Virology, Erasmus Medical Center, Rotterdam, Netherlands</nlm:aff></affiliation></author><author><name sortKey="De Kruif, John" sort="De Kruif, John" uniqKey="De Kruif J" first="John" last="De Kruif">John De Kruif</name><affiliation><nlm:aff id="aff1">Crucell Holland BV, Leiden, Netherlands</nlm:aff></affiliation></author><author><name sortKey="Preiser, Wolfgang" sort="Preiser, Wolfgang" uniqKey="Preiser W" first="Wolfgang" last="Preiser">Wolfgang Preiser</name><affiliation><nlm:aff id="aff2">Institute of Medical Virology, Johann Wolfgang Goethe University, Frankfurt am Main, Germany</nlm:aff></affiliation></author><author><name sortKey="Spaan, Willy" sort="Spaan, Willy" uniqKey="Spaan W" first="Willy" last="Spaan">Willy Spaan</name><affiliation><nlm:aff id="aff4">Department of Medical Microbiology, Leiden University Medical Centre, Leiden, Netherlands</nlm:aff></affiliation></author><author><name sortKey="Gelderblom, Hans R" sort="Gelderblom, Hans R" uniqKey="Gelderblom H" first="Hans R" last="Gelderblom">Hans R. Gelderblom</name><affiliation><nlm:aff id="aff3">Robert Koch-lnstitut, Berlin, Germany</nlm:aff></affiliation></author><author><name sortKey="Goudsmit, Jaap" sort="Goudsmit, Jaap" uniqKey="Goudsmit J" first="Jaap" last="Goudsmit">Jaap Goudsmit</name><affiliation><nlm:aff id="aff1">Crucell Holland BV, Leiden, Netherlands</nlm:aff></affiliation></author><author><name sortKey="Osterhaus, Albert Dme" sort="Osterhaus, Albert Dme" uniqKey="Osterhaus A" first="Albert Dme" last="Osterhaus">Albert Dme Osterhaus</name><affiliation><nlm:aff id="aff5">Department of Virology, Erasmus Medical Center, Rotterdam, Netherlands</nlm:aff></affiliation></author></analytic><series><title level="j">Lancet (London, England)</title><idno type="ISSN">0140-6736</idno><idno type="eISSN">1474-547X</idno><imprint><date when="2004">2004</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><title>Summary</title><p>SARS coronavirus continues to cause sporadic cases of severe acute respiratory syndrome (SARS) in China. No active or passive immunoprophylaxis for disease induced by SARS coronavirus is available. We investigated prophylaxis of SARS coronavirus infection with a neutralising human monoclonal antibody in ferrets, which can be readily infected with the virus. Prophylactic administration of the monoclonal antibody at 10 mg/kg reduced replication of SARS coronavirus in the lungs of infected ferrets by 3·3 logs (95% Cl 2·6–4·0 logs; p<0·001), completely prevented the development of SARS coronavirus-induced macroscopic lung pathology (p=0·013), and abolished shedding of virus in pharyngeal secretions. The data generated in this animal model show that administration of a human monoclonal antibody might offer a feasible and effective prophylaxis for the control of human SARS coronavirus infection.</p></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Guan, Y" uniqKey="Guan Y">Y Guan</name></author><author><name sortKey="Zheng, Bj" uniqKey="Zheng B">BJ Zheng</name></author><author><name sortKey="He, Yq" uniqKey="He Y">YQ He</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Subbarao, K" uniqKey="Subbarao K">K Subbarao</name></author><author><name sortKey="Mcauliffe, J" uniqKey="Mcauliffe J">J McAuliffe</name></author><author><name sortKey="Vogel, L" uniqKey="Vogel L">L Vogel</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Martina, Be" uniqKey="Martina B">BE Martina</name></author><author><name sortKey="Haagmans, Bl" uniqKey="Haagmans B">BL Haagmans</name></author><author><name sortKey="Kuiken, T" uniqKey="Kuiken T">T Kuiken</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tsang, Ot" uniqKey="Tsang O">OT Tsang</name></author><author><name sortKey="Chau, Tn" uniqKey="Chau T">TN Chau</name></author><author><name sortKey="Choi, Kw" uniqKey="Choi K">KW Choi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Parnes, C" uniqKey="Parnes C">C Parnes</name></author><author><name sortKey="Guillermin, J" uniqKey="Guillermin J">J Guillermin</name></author><author><name sortKey="Habersang, R" uniqKey="Habersang R">R Habersang</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="research-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Lancet</journal-id><journal-id journal-id-type="iso-abbrev">Lancet</journal-id><journal-title-group><journal-title>Lancet (London, England)</journal-title></journal-title-group><issn pub-type="ppub">0140-6736</issn><issn pub-type="epub">1474-547X</issn><publisher><publisher-name>Elsevier Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">15220038</article-id><article-id pub-id-type="pmc">7112500</article-id><article-id pub-id-type="publisher-id">S0140-6736(04)16506-9</article-id><article-id pub-id-type="doi">10.1016/S0140-6736(04)16506-9</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>ter Meulen</surname><given-names>Jan</given-names></name><degrees>MD</degrees><email>j.termeulen@crucell.com</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="cor1" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Bakker</surname><given-names>Alexander BH</given-names></name><degrees>PhD</degrees><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>van den Brink</surname><given-names>Edward N</given-names></name><degrees>PhD</degrees><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Weverling</surname><given-names>Gerrit J</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Martina</surname><given-names>Byron EE</given-names></name><degrees>PhD</degrees><xref rid="aff5" ref-type="aff">e</xref></contrib><contrib contrib-type="author"><name><surname>Haagmans</surname><given-names>Bart L</given-names></name><degrees>PhD</degrees><xref rid="aff5" ref-type="aff">e</xref></contrib><contrib contrib-type="author"><name><surname>Kuiken</surname><given-names>Thijs</given-names></name><degrees>PhD</degrees><xref rid="aff5" ref-type="aff">e</xref></contrib><contrib contrib-type="author"><name><surname>de Kruif</surname><given-names>John</given-names></name><degrees>PhD</degrees><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Preiser</surname><given-names>Wolfgang</given-names></name><degrees>MD</degrees><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Spaan</surname><given-names>Willy</given-names></name><degrees>PhD</degrees><xref rid="aff4" ref-type="aff">d</xref></contrib><contrib contrib-type="author"><name><surname>Gelderblom</surname><given-names>Hans R</given-names></name><degrees>MD</degrees><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name><surname>Goudsmit</surname><given-names>Jaap</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Osterhaus</surname><given-names>Albert DME</given-names></name><degrees>PhD</degrees><xref rid="aff5" ref-type="aff">e</xref></contrib></contrib-group><aff id="aff1"><label>a</label>Crucell Holland BV, Leiden, Netherlands</aff><aff id="aff2"><label>b</label>Institute of Medical Virology, Johann Wolfgang Goethe University, Frankfurt am Main, Germany</aff><aff id="aff3"><label>c</label>Robert Koch-lnstitut, Berlin, Germany</aff><aff id="aff4"><label>d</label>Department of Medical Microbiology, Leiden University Medical Centre, Leiden, Netherlands</aff><aff id="aff5"><label>e</label>Department of Virology, Erasmus Medical Center, Rotterdam, Netherlands</aff><author-notes><corresp id="cor1"><label>*</label>Correspondence to: Dr J ter Meulen, Crucell Holland BV, PO Box 2048, 2301 CA Leiden, Netherlands <email>j.termeulen@crucell.com</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>25</day><month>6</month><year>2004</year></pub-date><pmc-comment> PMC Release delay is 0 months and 0 days and was based on .</pmc-comment>
<pub-date pub-type="ppub"><day>26</day><month>6</month><year>2004</year></pub-date><pub-date pub-type="epub"><day>25</day><month>6</month><year>2004</year></pub-date><volume>363</volume><issue>9427</issue><fpage>2139</fpage><lpage>2141</lpage><permissions><copyright-statement>Copyright © 2004 Elsevier Ltd. All rights reserved.</copyright-statement><copyright-year>2004</copyright-year><copyright-holder>Elsevier Ltd</copyright-holder><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions><related-article related-article-type="article-reference" id="d32e287" ext-link-type="doi" xlink:href="10.1016/S0140-6736(04)16535-5"></related-article><abstract><title>Summary</title><p>SARS coronavirus continues to cause sporadic cases of severe acute respiratory syndrome (SARS) in China. No active or passive immunoprophylaxis for disease induced by SARS coronavirus is available. We investigated prophylaxis of SARS coronavirus infection with a neutralising human monoclonal antibody in ferrets, which can be readily infected with the virus. Prophylactic administration of the monoclonal antibody at 10 mg/kg reduced replication of SARS coronavirus in the lungs of infected ferrets by 3·3 logs (95% Cl 2·6–4·0 logs; p<0·001), completely prevented the development of SARS coronavirus-induced macroscopic lung pathology (p=0·013), and abolished shedding of virus in pharyngeal secretions. The data generated in this animal model show that administration of a human monoclonal antibody might offer a feasible and effective prophylaxis for the control of human SARS coronavirus infection.</p></abstract></article-meta></front><body><p id="para10">Severe acute respiratory syndrome (SARS) has emerged as a frequently fatal respiratory-tract infection caused by the newly identified SARS coronavirus. After the worldwide SARS epidemic in 2002–2003, sporadic cases continue to arise in southern China, possibly because of human contact with the animal reservoir.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref> Two recent cases of laboratory- acquired SARS coronavirus infections in China spread into the community and triggered extensive efforts in tracing and isolating contacts of patients to prevent a new epidemic. Means to control SARS coronavirus infection through active or passive immunisation are, therefore, urgently needed.</p><p id="para20">Passive transfer of mouse immune serum has been shown to reduce pulmonary viral titres in mice infected with SARS coronavirus.<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref> Immunoprophylaxis of SARS coronavirus infection with human monoclonal antibodies might therefore be a viable strategy to control SARS.</p><p id="para30">We generated a human IgG1 monoclonal antibody, CR3014, reactive with whole inactivated SARS corona- virus, by antibody phage display technology screening a large naive antibody library. Binding of this antibody to the viral peplomers was visualised by electron microscopy with indirect two-step immunogold labelling. SARS coronavirus from the supernatant of infected Vero cells was adsorbed to copper grids coated with carbon and Pioloform, which were incubated with the monoclonal antibodies by floating on droplets for 30 min at room temperature. Bound monoclonal antibodies were detected by incubation on droplets of anti-human-IgG-gold-5 nm conjugates (British Biocell, Cardiff, UK). The grids were negative contrasted with 1% uranyl acetate and assessed with a ZEISS EM 10 A transmission electron microscope (<xref rid="fig1" ref-type="fig">figure 1A, 1B</xref>). CR3014 was shown to react with the cell-surface expressed spike glycoprotein of SARS coronavirus: HEK293T cells were transfected with the plasmid-expressed, codon-optimised full-length glycoprotein spike, and stained with CR3014 and an R-phycoerythrin-labelled second antibody after 48 h using standard procedures for FACS-analysis (<xref rid="fig1" ref-type="fig">figure 1C</xref>). CR3014 was also shown to neutralise SARS coronavirus in vitro: triplicate wells of Vero cells were infected with 100 TCID<sub>50</sub> (50% tissue culture infective dose) of SARS coronavirus strain HK-39849, and pre-incubated for 1 h at 37°C with different concentrations of CR3014 or control antibody. The presence or absence of a cytopathic effect was scored in each well on day 5 after infection, and the percentage of protected wells was noted (<xref rid="fig1" ref-type="fig">figure 1D</xref>).<fig id="fig1"><label>Figure 1</label><caption><p>Binding of CR3014 monoclonal antibody to viral peplomers of SARS coronavirus (A, B) and to HEK293T cells expressing glycoprotein spike of SARS coronavirus (C), and in vitro neutralisation of SARS coronavirus strain HK-39849 (D)</p><p>Incubation with CR3014 led to a dense gold-label of the outer peplomer region of SARS coronavirus strain Frankfurt 1 (A), whereas a control human IgG1 monoclonal antibody did not induce any label (B). Bar indicates 100 nm. (C) Filled histogram=glycoprotein spike of SARS coronavirus, strain Frankfurt 1. Open histogram=control plasmid.</p></caption><graphic xlink:href="gr1_lrg"></graphic></fig></p><p id="para40">We tested the in-vivo potency of this antibody in ferrets, because these animals can be readily infected with SARS coronavirus by the intratracheal route, replicate the virus to high titres in the lung, and develop macroscopic and microscopic lung lesions.<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref> Experimental infection of ferrets with human respiratory viruses, including influenza viruses, is common practice, therefore procedures to work with these animals under the biocontainment conditions required for SARS coronavirus are well established. Approval for animal experiments was obtained from the institutional animal welfare committee.</p><p id="para50">In the first set of experiments, ferrets (<italic>Mustela furo</italic>, female, weight 800–900 g) were infected intratracheally with either 10<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref> TCID<sub>50</sub> or 10<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref> TCID<sub>50</sub> (n=8 for each group) of SARS coronavirus strain HKU-39849, which had been preincubated in 1 mL of cell-culture medium at 37°C for 1 h with either CR3014 or an human IgG1 control monoclonal antibody (n=4 for each group). The concentration of antibody in the medium was a 20-fold excess of the concentration theoretically needed for neutralisation of the challenge dose (0·13 mg/mL for the lower and 1·3 mg/mL for the higher challenge dose). Pharyngeal swabs were taken from the animals before challenge and on days 2, 4, and 7 after challenge, and frozen at –70°C before being subjected to quantitative RT- PCR. Two animals from each of the four groups were killed on days 4 and 7 and necropsies were done according to a standard protocol. For assessment of lung inflammation associated with SARS coronavirus infection, haematoxylineosin-stained sections from the cranial and caudal parts of the lung were examined for inflammatory foci by light microscopy with a 10× objective. For measurement of the SARS coronavirus titre, homogenates were prepared from 0·1–0·3 g of lung tissue pooled from cranial, medial, and caudal parts of the lung.</p><p id="para60">All control ferrets had high titres of SARS coronavirus in their lungs on day 4, and lower titres on day 7. Viral replication was accompanied by multifocal pulmonary lesions affecting about 5–10% of the surface area of the lung. Hislologically lesions consisled mainly of mild alveolar damage as well as peribronchial and perivascular lymphocyte infiltration. RT-PCR on pharyngeal swabs showed that virus was shed in the throal throughout day 7. Animals exposed to the mixture of virus and CR3014 had almost undetectable titres of SARS coronavirus in the lung, showed no lung lesions on day 4 or 7, and did not shed SARS coronavirus in their throats.</p><p id="para70">In the second set of experimenls, two groups of ferrets (n=4 in each group) received an intraperitoneal injection of either CR3014 or the control antibody at a concentration of 10 mg/kg, 24 h before intratracheal infection with 10<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref> TCID<sub>50</sub> SARS coronavirus, strain HKU-39849. Venous blood was drawn before administration of monoclonal antibody, before challenge, and on day 2 after the challenge. We measured the human IgG1 content of the serum by ELISA, and the neutralising capacity by a neutralisation assay using the fixed virus-varying serumdilution format. Pharyngeal swabs were taken from the animals before the inoculation and on days 2 and 4 after the challenge for quantitative RT-PCR. All animals were killed on day 4 and lung samples were taken as described for the first set of experiments.</p><p id="para80">The mean SARS coronavirus titre in lung homogenates of the animals given CR3014 was 3·3 logs lower than that of the control animals (95% CI 2·6–4·0 logs, p<0·001 [Student's <italic>t</italic> test]; <xref rid="fig2" ref-type="fig">figure 2A</xref>). This difference was accompanied by complete protection from macroscopic lung pathology (p=0·013 [Wilcoxon rank-sum test]; <xref rid="fig2" ref-type="fig">figure 2C</xref>) and a reduction of microscopic lesions compared with controls, which all showed multifocal lesions on gross necropsy (<xref rid="fig2" ref-type="fig">figure 2D</xref>). Shedding of SARS coronavirus in the throat was completely abolished in three of the four animals treated with CR3014 (<xref rid="fig2" ref-type="fig">figure 2B</xref>). However, in one animal the level of SARS coronavirus excretion was similar to that noted in the control group. The concentration of CR3014 in the serum of this ferret before challenge was less than 5 μg/mL, compared with 65–84 μg/mL in the other three animals, suggesting inappropriate antibody administration. Neutralising serum titres in this animal were less than half of those in the other animals on day 0 (titre of 5 against 100 TCID<sub>50</sub>), and were not detectable on day 2 after infection, compared with a titre of 5–10 against 100 TCID<sub>50</sub> in the other animals on day 2.<fig id="fig2"><label>Figure 2</label><caption><p>SARS coronavirus replication in lung tissue (A), shedding of SARS coronavirus in pharyngeal secretions (B), and macroscopic lung pathology (C,D) in ferrets</p><p>(A) SARS coronavirus titres in lung homogenates on day 4 after challenge shown as TCID<sub>50</sub>/mL. Horizontal bars indicate mean values. Dotted line shows lower detection limit of assay.(B) SARS coronavirus excretion measured by RT-PCR in pharyngeal swabs expressed as SARS coronavirus equivalents (eq), which equal TCID<sub>50</sub>. One animal in the CR3014 group, indicated by open circles, shed virus. (C) All CR3014-treated ferrets were free from macroscopic lung pathology, whereas all control ferrets showed multifocal lesions. (D) Left formalin-fixed lung (inflated with formalin by intrabronchial intubation)of a control ferret, with multifocal lesions (asterisks).</p></caption><graphic xlink:href="gr2_lrg"></graphic></fig></p><p id="para90">SARS coronavirus has been detected in nasopharyngeal aspirates of up to 72% of SARS patients, being associated with increased mortality, and in the lungs of all autopsied patients by viral isolation or RT-PCR.<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref> On the basis of our data and the successful prophylaxis of respiratory syncytial virus disease with a humanised monoclonal antibody (Palivizumab), we reason that immunoprophylaxis of SARS coronavirus infection with a human monoclonal antibody might be an option for the control of SARS.<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref> The prophylactic dose we used for CR3014 (10 mg/kg) is less than the 15 mg/kg dose at which Palivizumab is given intramuscularly to at-risk infants once a month. If CR3014 reduced the replication of SARS coronavirus in people to the same extent as in ferrets, and in view of the serum halflife of up to 20 days for IgG1 in human beings, one intramuscular administration of CR3014 at the dose used in this study should protect an adult for the length of at least one to two SARS coronavirus incubation periods (median 4–6 days). Passive immunisation with CR3014 might, therefore, be a feasible approach to prevent lung manifestations in people exposed to SARS coronavirus, and prevent person-to-person spread of the virus by abolishment of viral shedding in pharyngeal secretions.</p></body><back><ref-list id="bibl10"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="reference0005"><person-group person-group-type="author"><name><surname>Guan</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>BJ</given-names></name><name><surname>He</surname><given-names>YQ</given-names></name></person-group><article-title>Isolation and characterization of viruses related to the SARS coronavirus from animals in Southern China</article-title><source>Science</source><volume>302</volume><year>2003</year><fpage>276</fpage><lpage>278</lpage><pub-id pub-id-type="pmid">12958366</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="reference0010"><person-group person-group-type="author"><name><surname>Subbarao</surname><given-names>K</given-names></name><name><surname>McAuliffe</surname><given-names>J</given-names></name><name><surname>Vogel</surname><given-names>L</given-names></name></person-group><article-title>Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice</article-title><source>J Virol</source><volume>78</volume><year>2004</year><fpage>3572</fpage><lpage>3577</lpage><pub-id pub-id-type="pmid">15016880</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="reference0015"><person-group person-group-type="author"><name><surname>Martina</surname><given-names>BE</given-names></name><name><surname>Haagmans</surname><given-names>BL</given-names></name><name><surname>Kuiken</surname><given-names>T</given-names></name></person-group><article-title>SARS virus infection in cats and ferrets</article-title><source>Nature</source><volume>425</volume><year>2003</year><fpage>915</fpage><pub-id pub-id-type="pmid">14586458</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="reference0020"><person-group person-group-type="author"><name><surname>Tsang</surname><given-names>OT</given-names></name><name><surname>Chau</surname><given-names>TN</given-names></name><name><surname>Choi</surname><given-names>KW</given-names></name></person-group><article-title>Coronavirus-positive nasopharyngeal aspirate as predictor for severe acute respiratory syndrome mortality</article-title><source>Emerg lnf Dis</source><volume>9</volume><year>2003</year><fpage>1381</fpage><lpage>1387</lpage></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="reference0025"><person-group person-group-type="author"><name><surname>Parnes</surname><given-names>C</given-names></name><name><surname>Guillermin</surname><given-names>J</given-names></name><name><surname>Habersang</surname><given-names>R</given-names></name></person-group><article-title>Palivizumab prophylaxis of respiratory syncytial virus disease in 2000–2001: results from The Palivizumab Outcomes Registry</article-title><source>Pediatr Pulmonol</source><volume>35</volume><year>2003</year><fpage>484</fpage><lpage>489</lpage><pub-id pub-id-type="pmid">12746948</pub-id></element-citation></ref></ref-list><ack><sec><title>Acknowledgments</title><p>SARS coronavirus strain HKU-39849 was provided by Malik Peiris, Department of Microbiology, University of Hong Kong. We thank Geert van Amerongen and Roberto Dias d'Ullois for technical support in the animal studies, and Frank Pistoor (ViroClinics), James Simon (CoroNovative), and Jindrich Cinatl for logistical support of the studies. We thank Rob van Lavieren, Freek Cox, Mandy Jongeneelen, Gabi Bauer, and Andrea Mannel for excellent technical assistance.</p></sec></ack><ack><title>Contributors</title><p>J ter Meulen, A B H Bakker, G J Weverling, J Goudsmit, and A D M E Osterhaus planned the study, analysed data, and wrote the report. E N van den Brink, J de Kruif, W Preiser, and W Spaan generated and characterised the recombinant antibody. H R Gelderblom did electron microscopy. B E E Martina and B L Haagmans did animal experiments and virus titrations. T Kuiken did pathological analysis. All authors saw and approved the final version of the manuscript.</p></ack><ack><title>Conflict of interest statement</title><p>The animal studies at the Erasmus University, Rotterdam, were funded by Crucell Holland BV. The sponsor was involved in the design of the animal studies and in data analysis, but was not involved in performing the animal studies or the virological or pathological analysis of the necropsy samples.</p></ack></back></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001256 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 001256 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé= PMC:7112500
|texte= Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i -Sk "pubmed:15220038" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |